Tracers / [225Ac]Ac-DOTA-CCK-66
[225Ac]Ac-DOTA-CCK-66
Also written as [Ac-225]Ac-DOTA-CCK-66
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated minigastrin analog (peptide)
- Target / mechanism
- Cholecystokinin-2 (CCK2)/gastrin receptor targeting minigastrin analog PMID 39392495
- Clinical application
- Targeted alpha therapy (TAT) for medullary thyroid carcinoma (MTC) PMID 39392495
- Theranostic pair
- <a href="/tracers/ga68-dotacck66/">ga68-dotacck66</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | >99% no | >95% | DOTA-CCK-66 | 39392495 2025 Eur J Nucl Med Mol Imaging 225Ac-labeling of the peptide precursor was performed manually — resulting in quantitative radiochemical yields (RCYs, > 99%, non-decay corrected) |
Need this precursor?We can point you to suppliers for [225Ac]Ac-DOTA-CCK-66, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Stage set/updated at stage 23 from PMID 39392495: 'Preclinical evaluation of 225Ac-labeled minigastrin analog DOTA-CCK-66 for Targeted Alpha Therapy.'.